表紙
市場調查報告書

非小細胞肺癌治療藥的全球市場:2019年∼2023年

Global Non-Small Cell Lung Cancer Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 806187
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
非小細胞肺癌治療藥的全球市場:2019年∼2023年 Global Non-Small Cell Lung Cancer Drugs Market 2019-2023
出版日期: 2019年03月06日內容資訊: 英文 124 Pages
簡介

非小細胞肺癌的罹患率和發生率的增加,成為帶動全球非小細胞肺癌治療藥市場成長的主要原因之一。因為抽煙、大氣污染、二手煙、職業性暴露等危險因素高漲,全球非小細胞肺癌的發生率上升,導致非小細胞肺癌治療藥的需求增加。 Technavio的分析師預測,全球非小細胞肺癌治療藥市場至2023年,預測將以13%以上的年複合成長率成長。

本報告提供全球非小細胞肺癌治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 生技藥品
  • 小細胞標靶治療
  • 化療
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR30977

About this market

The increasing prevalence and incidence of non-small cell lung cancer are one of the primary factors driving the global non-small cell lung cancer drugs market growth. The growing risk factors such as cigarette smoking, air pollution, secondary smoking, and occupational exposure is increasing the incidence of non-small cell lung cancer across the world. This will lead to an increase in the demand for non-small cell lung cancer drugs. Technavio's analysts have predicted that the non-small cell lung cancer drugs market will register a CAGR of over 13% by 2023.

Market Overview

Strong drug pipeline and recent drug approvals

One of the growth drivers of the global non-small cell lung cancer drugs market is the strong drug pipeline and recent drug approvals. The development of new drugs and their approvals are helpful for the treatment of non-small lung cancer, which is expected to drive the market during the forecast period.

The high cost of treatment

One of the challenges in the growth of global non-small cell lung cancer drugs market is the high cost of treatment. Non-small cell lung cancer can be treated by surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapy which is very costly. Therefore, the high cost of treatment for non-small cell lung cancer will hamper the growth of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the non-small cell lung cancer drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several vendors. The vendors in the market are using predictive biomarkers for the development of cost-effective therapies with improved clinical benefits. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Biologics - Market size and forecast 2018-2023
  • Small molecule targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

Back to Top